NCT05617898 Determining the Role of Social Reward Learning in Social Anhedonia
| NCT ID | NCT05617898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Psychosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 152 participants |
| Start Date | 2023-06-14 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 152 participants in total. It began in 2023-06-14 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a clinical trial study that aims to evaluate the specificity of the relationship between reduced sensitivity to social reward and social anhedonia at both behavioral and neural levels. Individuals who recently experienced their first-episode psychosis will be recruited. Participants will be randomized 1:1 to motivational interviewing or a time- and format-matched control probe. At pre- and post-probe, participants will perform two social reward learning tasks in the scanner. With this design feature, we will examine the relationship between sensitivity to social reward and reduced subjective experience of social pleasure at both the behavioral and neural levels.
Eligibility Criteria
Inclusion Criteria: * Age 18-35 years * A first episode of a psychotic illness that began within the past three years * Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder * Taking 2nd generation antipsychotic medications * Estimated premorbid IQ not less than 70 as assessed with the Wechsler Test of Adult Reading * Appropriate for scanning (i.e., no pacemaker or metal implants) and expressed willingness to participate in scanning * Sufficient fluency in English to comprehend testing procedures * Corrected vision of at least 20/30 Exclusion Criteria: * No evidence that substance use makes the diagnosis ambiguous (rule out substance-induced psychosis) * No evidence of moderate or severe alcohol or substance use disorder in the past 3 months * No clinically significant disease based on medical history (e.g., epilepsy) or significant head injury * For females: no current pregnancy * No sedatives or anxiolytics on the day of assessment * No medication change 3 weeks prior to enrollment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05617898 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05617898 currently recruiting?
Yes, NCT05617898 is actively recruiting participants. Contact the research team at jungheelee@uabmc.edu for enrollment information.
Where is the NCT05617898 trial being conducted?
This trial is being conducted at Birmingham, United States, Los Angeles, United States.
Who is sponsoring the NCT05617898 clinical trial?
NCT05617898 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 152 participants.